News Conference News EAS 2025 Back From the Brink: Obicetrapib Performs Well in BROADWAY, TANDEM Yael L. Maxwell May 08, 2025
News Conference News EAS 2023 With New LDL Goalposts in FH, Combo Therapy Must Start Early Michael O'Riordan May 29, 2023
News Conference News EAS 2022 Most Kids With FH Diagnosed by Cascade Screening, Albeit Late and Ineffectively Michael O'Riordan May 27, 2022
News Conference News EAS 2022 Elevated Risks From Lp(a) Can Be Offset by Lower Lifetime LDL Cholesterol Michael O'Riordan May 26, 2022
News Conference News EAS 2022 Lp(a) Linked to ASCVD and Aortic Stenosis Regardless of CRP Level Michael O'Riordan May 24, 2022
News Conference News EAS 2022 ROSE Trial: CETP Inhibitor Shows Promise as Oral Add-on for LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2022 Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering Michael O'Riordan May 24, 2022
News Conference News EAS 2018 Unlocking Lp(a): Baseline Levels Matter, but So Too Does Absolute Reduction Yael L. Maxwell May 08, 2018
News Conference News EAS 2017 FOURIER in Focus: Costs, Patient Selection, Combination Therapy, and Safety Debated as Lipid Experts Digest the Data Yael L. Maxwell April 26, 2017
News Conference News EAS 2017 Is Atherosclerosis an LDL-Cholesterol or Immune Disease? The Answer May Be Both Yael L. Maxwell April 25, 2017
News Conference News EAS 2017 EAS Consensus Document Strives to Banish Skepticism Over LDL Cholesterol’s Causal Role in Atherosclerosis Yael L. Maxwell April 24, 2017
News Conference News EAS 2016 Preservation of LDL Cholesterol Targets for Lipid Lowering in New European Guidance Gets Blessing of Prevention Experts Yael L. Maxwell June 06, 2016
News Conference News EAS 2016 Statin-Associated Muscle Symptoms: Real or ‘Artificial,’ Physicians Should Take Time to Manage Patients Yael L. Maxwell June 01, 2016